725 related articles for article (PubMed ID: 24477151)
1. Warfarin therapy for atrial fibrillation in general practice--is bleeding risk underestimated?
Bratland B; Hornnes MB
Tidsskr Nor Laegeforen; 2014 Jan; 134(2):175-9. PubMed ID: 24477151
[TBL] [Abstract][Full Text] [Related]
2. Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey.
Marcucci M; Lip GY; Nieuwlaat R; Pisters R; Crijns HJ; Iorio A
Am J Med; 2014 Oct; 127(10):979-986.e2. PubMed ID: 24838192
[TBL] [Abstract][Full Text] [Related]
3. Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation.
Overvad TF; Larsen TB; Albertsen IE; Rasmussen LH; Lip GY
Expert Rev Cardiovasc Ther; 2013 Dec; 11(12):1619-29. PubMed ID: 24215192
[TBL] [Abstract][Full Text] [Related]
4. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
5. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience.
Barnes GD; Gu X; Haymart B; Kline-Rogers E; Almany S; Kozlowski J; Besley D; Krol GD; Froehlich JB; Kaatz S
Thromb Res; 2014 Aug; 134(2):294-9. PubMed ID: 24929840
[TBL] [Abstract][Full Text] [Related]
6. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?
Ruiz-Nodar JM; Marín F; Roldán V; Valencia J; Manzano-Fernández S; Caballero L; Hurtado JA; Sogorb F; Valdés M; Lip GY
Circ Cardiovasc Interv; 2012 Aug; 5(4):459-66. PubMed ID: 22787018
[TBL] [Abstract][Full Text] [Related]
7. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.
Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L
J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375
[TBL] [Abstract][Full Text] [Related]
8. Bleeding risk assessment in patients with atrial fibrillation who are taking oral anticoagulants.
Guo Y; Lip GY; Apostolakis S
Hosp Pract (1995); 2013 Feb; 41(1):71-8. PubMed ID: 23466969
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial.
Apostolakis S; Lane DA; Buller H; Lip GY
Thromb Haemost; 2013 Nov; 110(5):1074-9. PubMed ID: 24048467
[TBL] [Abstract][Full Text] [Related]
10. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.
Lip GY; Frison L; Halperin JL; Lane DA
J Am Coll Cardiol; 2011 Jan; 57(2):173-80. PubMed ID: 21111555
[TBL] [Abstract][Full Text] [Related]
11. Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation.
Siu CW; Tse HF
Circ Arrhythm Electrophysiol; 2014 Apr; 7(2):300-6. PubMed ID: 24610776
[TBL] [Abstract][Full Text] [Related]
12. Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation.
Marcucci M; Nobili A; Tettamanti M; Iorio A; Pasina L; Djade CD; Franchi C; Marengoni A; Salerno F; Corrao S; Violi F; Mannucci PM;
Eur J Intern Med; 2013 Dec; 24(8):800-6. PubMed ID: 24035703
[TBL] [Abstract][Full Text] [Related]
13. Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores.
Proietti M; Rivera-Caravaca JM; Esteve-Pastor MA; Marín F; Lip GYH
Thromb Haemost; 2021 Aug; 121(8):1107-1114. PubMed ID: 33296920
[TBL] [Abstract][Full Text] [Related]
14. [Atrial fibrillation and stroke].
Aamodt AH; Sandset PM; Atar D; Tveit A; Russell D
Tidsskr Nor Laegeforen; 2013 Aug; 133(14):1453-7. PubMed ID: 23929293
[TBL] [Abstract][Full Text] [Related]
15. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
Bonde AN; Lip GY; Kamper AL; Hansen PR; Lamberts M; Hommel K; Hansen ML; Gislason GH; Torp-Pedersen C; Olesen JB
J Am Coll Cardiol; 2014 Dec; 64(23):2471-82. PubMed ID: 25500231
[TBL] [Abstract][Full Text] [Related]
16. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study.
Apostolakis S; Lane DA; Guo Y; Buller H; Lip GY
J Am Coll Cardiol; 2012 Aug; 60(9):861-7. PubMed ID: 22858389
[TBL] [Abstract][Full Text] [Related]
17. Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study.
Wang SV; Franklin JM; Glynn RJ; Schneeweiss S; Eddings W; Gagne JJ
BMJ; 2016 May; 353():i2607. PubMed ID: 27221664
[TBL] [Abstract][Full Text] [Related]
18. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
Cairns JA; Connolly S; McMurtry S; Stephenson M; Talajic M;
Can J Cardiol; 2011; 27(1):74-90. PubMed ID: 21329865
[TBL] [Abstract][Full Text] [Related]
19. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation.
Hylek EM
Thromb Haemost; 2008 Jul; 100(1):16-7. PubMed ID: 18612532
[No Abstract] [Full Text] [Related]
20. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
